Report of Foreign Issuer (6-k)
December 15 2017 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
December 15, 2017
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Ozempic® (semaglutide)
recommended for approval by the European regulatory authorities
Bagsværd, Denmark, 15 December 2017
-
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines
Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Ozempic
®
(semaglutide) for the treatment of adults with type 2 diabetes mellitus.
The CHMP recommends Ozempic
®
,
the intended brand name for once-weekly semaglutide, to be indicated as monotherapy when metformin no longer provides sufficient
treatment or is contraindicated and as an addition to other medicinal products for the treatment of diabetes. The indication also
refers to specific sections of the label for study results with respect to combination with other diabetes medications, effects
on glycaemic control, cardiovascular events and the populations studied. The label furthermore reflects the superior reduction
in body weight achieved with Ozempic
®
relative to comparator treatments and the statistically
significant reduction in diabetic nephropathy with Ozempic
®
relative to standard of care.
As an integral part of the approval, Novo Nordisk
has committed to conduct post- approval safety studies including a long-term diabetic retinopathy outcome study. Furthermore, as
required for all long-acting GLP-1 products approved in the EU, Ozempic
®
will be enrolled
in the data collection for the registry of medullary thyroid carcinoma.
“We are very excited about the positive
opinion for Ozempic
®
for treatment of people with type 2 diabetes in Europe, many of whom
are still looking for new and more efficacious solutions to better manage their disease,” said Mads Krogsgaard Thomsen, executive
vice president and chief science officer. “We believe Ozempic
®
, with its unique
clinical profile, has the potential to set a new standard for treatment of type 2 diabetes.”
Novo Nordisk expects to receive final marketing
authorisation from the European Commission in the first quarter of 2018.
About Ozempic
®
Ozempic
®
(semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type
2 diabetes. The review of
Page 2 of 2
Ozempic
®
is based on the SUSTAIN programme, a global clinical development programme that comprises eight phase 3a trials, encompassing more
than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including
some individuals with high cardiovascular risk profiles and people with and without renal disease.
Ozempic
®
was recently approved by the US Food and Drug Administration and is currently under review by several regulatory agencies, including
the Japanese Pharmaceuticals and Medical Devices Agency.
Novo Nordisk is a global healthcare company with more than
90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable
us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark,
Novo Nordisk employs approximately 41,700 people in 77 countries, and markets its products in more than 165 countries. Novo Nordisk’s
B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information,
visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
Katrine Sperling
|
+45 4442 6718
|
krsp@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Hanna Ögren
|
+45 3079 8519
|
haoe@novonordisk.com
|
Anders Mikkelsen
|
+45 3079 4461
|
armk@novonordisk.com
|
Christina Kjær
|
+45 3079 3009
|
cnje@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 92 / 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: December 15, 2017
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024